Zheng Ran 4

What Happened

• Zheng Ran, a director of Caribou Biosciences, received a grant of 45,000 derivative shares on February 20, 2026. The filing reports an acquisition price of $0.00 per share (total reported value $0) and classifies the transaction as an award/grant (code A).
• This is an award of derivative securities (per the Form 4), not a sale. It represents potential future ownership subject to vesting rather than an immediate open-market purchase.

Key Details

• Transaction date: 2026-02-20; Transaction type: Award/Grant (code A).
• Amount: 45,000 derivative shares; reported price: $0.00; reported total: $0.
• Vesting: One‑twelfth of the award vests each monthly anniversary of the grant date; fully vested on February 20, 2027, subject to continued service (footnote F1).
• Shares owned after the transaction: not specified in the public Form 4 filing.
• Filing timeliness: Reported on 2026-02-20 (same day as the transaction per the filing), so appears timely.

Context

• Because this is a derivative award with a scheduled vesting plan, the award does not represent immediately tradable stock unless and until vested and (if applicable) exercised or settled. It is not an indicated sale or market disposition.
• For retail investors, awards like this are routine compensation for insiders; they show potential future dilution but are not a direct cash in/out signal.